Earnings Call · Q2 FY2025·2025-07-30

Q2 25EPS 0.00%·Rev n/aQ1 25EPS -100.00%*·Rev n/aQ4 24EPS -27.27%·Rev n/aQ3 24EPS -100.00%*·Rev n/a⚠ consensus missing

Anika Therapeutics, Inc. ANIK

Matt Hall — Director, Corporate Development and Investor Relations

Cheryl Renee Blanchard — Chief Executive Officer

Stephen D. Griffin — Chief Financial Officer

−27.4%1d on move date−27.3% vs SPY3d−22.6%5d−25.2%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ANIK calls or request research access.

More ANIK calls Browse calls Request research access